Compare VanEck Junior Gold Miners (GDXJ) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Junior Gold Miners vs Gilead Sciences, Inc. — how do they compare? VanEck Junior Gold Miners trades at $114.43 (market cap $8.22B), while Gilead Sciences, Inc. trades at $151.17 (market cap $182.40B). The key difference: Gilead Sciences, Inc. is far larger — about 22.2× VanEck Junior Gold Miners's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while VanEck Junior Gold Miners pays none. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Junior Gold Miners for 41 Days and Gilead Sciences, Inc. for 111 Days on average.
| GDXJ | GILD | |
|---|---|---|
Market Cap | $8.22B | $182.40B |
Volume | 3,212,198 | 4,469,821 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $156.19 | $155.80 |
52-Week Low | $87.56 | $117.18 |
Typical Hold Time | 41 Days | 111 Days |
Enterprise Value | — | $205.46B |
Dividend Yield | — | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GDXJ, the VanEck Junior Gold Miners ETF, trades at $110.91, up 1.62% today. The technical outlook is bearish with moving averages signaling a downtrend, while oscillators are neutral. Recent news highlights multiple junior gold mining companies being added to the ETF's index, potentially broadening its investor base. Key support is at $110, with resistance at $112.
The outlook remains cautious due to the bearish technical structure and reliance on gold price volatility. Opportunities exist if gold rallies, but risks include sector-specific volatility and macroeconomic factors affecting mining stocks. Investor sentiment is mixed, with institutional activity showing some selling pressure.
Gilead Sciences (GILD) trades at $147.10, up 0.17% on the day, with a bullish technical signal and strong analyst consensus. Recent earnings have mostly beaten expectations, though Q2 2026 saw a significant loss. The company maintains robust operating cash flow and has expanded access to its HIV prevention drug lenacapavir in Latin America, signaling growth potential in its core franchises.
The outlook is positive given analyst buy ratings and a $151.57 price target, but risks include negative net income margin and ROE in 2026, high debt levels, and reliance on pipeline success. The stock offers value if HIV and oncology advances materialize, yet investors face volatility from earnings inconsistencies and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Junior Gold Miners
GDXJ provides exposure to small and mid-cap companies in the global gold and silver mining industry. It focuses on 'junior' miners involved in exploration and early production, featuring 2026 leaders like Pan American Silver and Coeur Mining.
Read more on GDXJ →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
